What Makes Ebola So Deadly

J Virol. 2003 Sep; 77(18): 9733–9737.

Ebola Virus Pathogenesis: Implications for Vaccines and Therapies

Nancy Sullivan

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Zhi-Yong Yang

Vaccine Research Middle, National Plant of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Gary J. Nabel

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Ebola virus is an aggressive pathogen that causes a highly lethal hemorrhagic fever syndrome in humans and nonhuman primates. First recognized near the Ebola River valley during an outbreak in Zaire in 1976 (half-dozen, 20), outbreaks have occurred in Africa in the ensuing 27 years, with mortality rates ranging from 50 to ninety% (26, 28). Outbreaks take been identified yearly for the past 3 years in cardinal Africa, the most recent of which continues in the Republic of the congo, with more than 125 fatalities to date according to the World Health Organization (http://www.who.int/csr/don/2003_05_07/en/, accessed seven May 2003). The natural host for Ebola virus is unknown, and then it has non been possible to implement programs to control or eliminate viral reservoirs of manual to homo populations. The rapid progression of Ebola virus infection has further complicated the command of this disease, affording lilliputian opportunity to develop acquired amnesty. There is currently no antiviral therapy or vaccine that is effective against Ebola virus infection in humans.

Although its clinical grade is well known, the specific mechanisms underlying the pathogenicity of Ebola virus accept not been clearly delineated. This is due, in part, to the difficulty in obtaining samples and studying the affliction in the relatively remote areas in which the outbreaks occur. In improver, a high degree of biohazard containment is required for laboratory studies and clinical analysis. Isolation of the viral cDNAs and the evolution of expression systems have immune the report of Ebola virus factor products under less restrictive conditions and facilitated an understanding of the mechanisms underlying virally induced cell impairment.

EBOLA VIRUS DISEASE PROGRESSION

Typically, Ebola virus infection runs its course within 14 to 21 days. Infection initially presents with nonspecific flu-like symptoms such as fever, myalgia, and malaise. Equally the infection progresses, patients exhibit severe bleeding and coagulation abnormalities, including gastrointestinal bleeding, rash, and a range of hematological irregularities, such as lymphopenia and neutrophilia. Cytokines are released when reticuloendothelial cells encounter virus, which tin contribute to exaggerated inflammatory responses that are not protective. Damage to the liver, combined with massive viremia, leads to disseminated intravascular coagulopathy. The virus eventually infects microvascular endothelial cells and compromises vascular integrity. The final stages of Ebola virus infection usually include lengthened bleeding, and hypotensive daze accounts for many Ebola virus fatalities (for reviews, run into references 9 and 28).

STRUCTURE AND CLASSIFICATION OF THE EBOLA VIRUS

Ebola virus and the related Marburg virus are members of the Filovirus family, which are pleomorphic, negative-sense RNA viruses whose genome organization is virtually similar to the Paramyxoviridae. Of the 4 identified strains of Ebola virus, iii—the Zaire, Ivory Coast, and Sudan strains—accept been shown to cause disease in both humans and nonhuman primates, with the Zaire strain exhibiting the highest lethality rate (13, 29). The only documented outbreaks of Ebola virus infection in the United States were fortunately restricted to nonhuman primates at holding facilities in Virginia and Texas, acquired past the Reston strain, which has not however acquired fatal affliction in humans (19).

The Ebola virus genome is 19 kb long, with seven open reading frames encoding structural proteins, including the virion envelope glycoprotein (GP), nucleoprotein (NP), and matrix proteins VP24 and VP40; nonstructural proteins, including VP30 and VP35; and the viral polymerase (reviewed in reference 28). Unlike that of Marburg virus, the GP open reading frame of Ebola virus gives rise to two gene products, a soluble sixty- to seventy-kDa protein (sGP) and a full-length 150- to 170-kDa protein (GP) that inserts into the viral membrane (29, 41), through transcriptional editing.

EBOLA VIRUS GP AND VIRAL PATHOGENESIS

The Ebola virus GP is synthesized in a secreted (sGP) or full-length transmembrane form, and each factor product has distinct biochemical and biological properties. For instance, GP appears to class a trimeric circuitous (30) and binds preferentially to endothelial cells, whereas sGP does not (49). Preferential binding of Ebola virus GP to the endothelium was demonstrated by use of two independent methodologies as follows: direct binding was assessed past fluorescence-activated jail cell sorter assay, and pseudotyping experiments were performed in which virus titers, jail cell numbers, and confluence were advisedly determined then that the multiplicity of infection was controlled and equal in all prison cell types. Another study failed to demonstrate this preferential binding (17), but directly bounden of GP to endothelial cells was not measured and neither the multiplicity of infection, target cell numbers, nor cell confluence was reported in that study. The receptors required for jail cell binding and infection are non completely understood. A folate-related receptor can serve equally a cofactor to facilitate infection (8), but whether information technology serves as a receptor remains unclear. The cell surface lectin DC-SIGN tin can also facilitate GP bounden to cells through viral saccharide determinants, but it does not appear to mediate entry past itself (1, 32). In contrast to GP, sGP gives rise to a dimeric protein (30) that interacts with neutrophils (49). sGP mediates neutrophil binding, directly or indirectly, through CD16b, the neutrophil-specific form of the Fcγ receptor Iii (49). Afterward the initial clarification of the neutrophil binding of sGP, it was shown that immunoglobulin Thousand (IgG), but not an Fab fragment, against sGP was needed to detect neutrophil binding (T. Maruyama, M. J. Buchmeier, P. W. H. I. Parren, and D. R. Burton, Technical Annotate, Scientific discipline 282:843-844, 1998). A subsequent study showed that the binding could also be seen if an irrelevant IgG was used with the Fab fragment confronting sGP (Z.-Y. Yang, R. Delgado, L. Xu, R. F. Todd, East. G. Nabel, A. Sanchez, and G. J. Nabel, Writer's Answer, Science 282:844-846, 1998). Though such binding could potentially arise from bounden of allowed complexes, boosted studies using resonance free energy transfer showed that neutrophils incubated with sGP showed a pregnant reduction in the CR3-Fcγ RIIIB RET signal (22), demonstrating that sGP alters the physical and functional interaction between Fcγ RIIIB and CR3. Through this interaction, sGP may contribute to immune evasion past inhibiting early steps in neutrophil activation (as measured by the downward-modulation of l-selectin) that would ordinarily assistance in virus clearance (49).

Several lines of bear witness propose that the viral GP plays a key office in the manifestations of Ebola virus infection. The transmembrane form of GP targets the Ebola virus to cells that are relevant to its pathogenesis. Specifically, GP allows the virus to introduce its contents into monocytes and/or macrophages, where prison cell impairment or exposure to viral particles may cause the release of cytokines (34) associated with inflammation and fever, and into endothelial cells, which damages vascular integrity (48) (Fig. 1). Thus, sGP may alter the immune response by inhibiting neutrophil activation, while the transmembrane GP may contribute to the hemorrhagic fever symptoms by targeting virus to cells of the reticuloendothelial network and the lining of blood vessels.

An external file that holds a picture, illustration, etc. Object name is jv1830358001.jpg

Host allowed responses to Ebola virus and cell harm due to direct infection of monocytes and macrophages cause the release of cytokines associated with inflammation and fever (A). Infection of endothelial cells too induces a cytopathic result and damage to the endothelial barrier that, together with cytokine effects, leads to the loss of vascular integrity (B). Transient expression of Ebola virus GP in human umbilical vein endothelial cells or 293T cells causes a reduction of specific integrins (primary molecules responsible for prison cell adhesion to the extracellular matrix) and immune molecules on the cell surface. Cytokine dysregulation and virus infection may synergize at the endothelial surface, promoting hemorrhage and vasomotor collapse.

GP expression in cultured human being endothelial and epithelial cells causes cell rounding and detachment (48). GP is the only one of the seven Ebola virus gene products to exert this issue, and though GP from all four documented Ebola virus strains acts similarly, the highly pathogenic Zaire strain has the nearly potent action in this cell culture assay (33). These effects require the presence of the mucin-like, serine-and-threonine-rich domain of GP and correspond with the down-regulation of specific molecules on the cell surface (48). Cytotoxicity appears to be precisely controlled past a machinery involving down-regulation of GP expression through a transcriptional RNA editing upshot past the viral polymerase. The importance of this phenomenon was shown by apply of a reverse genetics system for replicating Ebola virus in which a mutation that increases the level of full-length GP expression is significantly more cytotoxic than the wild-type virus (42).

The in vivo relevance of GP-induced endothelial prison cell toxicity was explored in blood vessel explants (48) in which human saphenous veins were infected with replication-lacking adenoviral vectors conveying the cistron for GP or sGP. Staining with horseradish peroxidase and scanning electron microscopy were used to observe astringent damage to the endothelial jail cell lining in vessels that received the virus encoding full-length Ebola virus GP only not sGP or vectors in which the mucin domain of GP was removed. Cell damage in explant cultures paralleled the species specificity of different Ebola virus strains: no toxicity was observed when Reston strain GP was introduced into human vascular explants, whereas significant tissue damage was observed in vascular explants from nonhuman primates.

Farther in vitro analyses have begun to elucidate the molecular mechanisms underlying GP-induced cytotoxicity. Critical mediators of cell adhesion to the matrix and immune signaling (e.g., integrins and major histocompatibility complex class I jail cell surface proteins) are among the prison cell surface molecules that are dysregulated (33, 37). Transient expression of Ebola virus GP in man kidney 293T cells acquired a reduction of specific integrins (chief molecules responsible for cell adhesion to the extracellular matrix) on the cell surface. GP mutants lacking the membrane-spanning region of the ectodomain did not cause this down-regulation, suggesting that anchorage of GP to the cell membrane is required for this effect. Disruption of major histocompatibility complex grade I expression on the cell surface is a mechanism for evading host allowed responses that is shared by several pathogens, including cytomegalovirus, man immunodeficiency virus (HIV), and herpesviruses (27). It is non known whether GP affects integrin levels by altering intracellular trafficking or by modulation of protein synthesis or degradation, merely preliminary experiments propose a role for cellular protein transport machinery in GP-mediated cytotoxicity (Northward. Sullivan, unpublished observations). In whatsoever event, the biologic effects of GP lonely may account largely for the features of Ebola virus infection that atomic number 82 to fatal illness, including inflammatory dysregulation, immune suppression, and loss of vascular integrity.

Structural analyses of GP have revealed features in common with other viral envelope proteins. The crystal construction of the GP ectodomain revealed a coiled-coil domain resembling a trimer of helical hairpin-similar loops (23, 44). The hairpin structure is adjacent to the fusion-peptide region (16) hypothesized to insert directly into the target cell membrane. Analogous coiled-coil regions have been defined for GPs of flu virus, murine retroviruses, HIV, and simian immunodeficiency virus (SIV) every bit well as for some cellular proteins, called SNARES, that function in intracellular vesicle fusion (44). For HIV gp160, information technology has been possible to identify peptides that bind to a transient intermediate form that precedes hairpin germination. Because of their potent inhibition of viral entry, these reagents have shown considerable promise in clinical trials (21). The Ebola virus GP contains a homologous hairpin structure for which a possible inhibitory peptide has been identified (43), a region that remains a potential therapeutic target.

Immune RESPONSE TO EBOLA VIRUS INFECTION

Ebola virus replicates at an unusually high rate that overwhelms the protein synthesis apparatus of infected cells and host immune defenses (28). Both the adaptive immune and inflammatory systems respond to infection at the same fourth dimension that some prison cell types, specifically monocytes and macrophages, are targets relevant to disease pathogenesis. This feature of the infection was initially suggested past the immunohistochemical localization of Ebola virus in vivo: endothelial cells, mononuclear phagocytes, and hepatocytes are the master targets of infection (three, four, 12, l).

The components of the immune system that may protect confronting Ebola virus infection have non been divers. Antibody titers against Ebola virus GPs are readily detectable in patients who recover from Ebola virus infection; notwithstanding, anecdotal reports accept indicated that serum from recovered patients did not consistently protect against infection or showroom neutralization of virus replication in cell culture. Furthermore, passive transfer of antibodies in creature models just delays the onset of symptoms and does not modify overall survival (xviii). More than recently, the neutralization of virus replication by selected monoclonal antibodies isolated from the bone marrow of recovered patients was demonstrated in vitro (24), and monoclonal antibodies that recognize specific epitopes of Ebola virus GP have been shown to confer immune protection in a murine model of Ebola virus infection (xv, 45) and in guinea pigs (25). Notwithstanding, information technology is relatively easy to protect against infection in the mouse model, and protection of guinea pigs required a loftier dose of antibody administered very close to the fourth dimension of virus challenge. Taken together, these results suggest that antibodies alone do not provide protective immunity in a natural context and that cellular immunity is likely to play a significant role in virus clearance. Whether hyperimmune serum from surviving vaccinated animals or certain infrequently occurring antibodies are capable of attenuating infection remains unknown, but such antibodies could potentially contribute to therapy if they tin can be identified and optimized.

A comparison of immune parameters in survivors and nonsurvivors of infection has provided clues into the constituents of an constructive immune response. Baize et al. (2) characterized the immune responses of patients in ii large Ebola virus outbreaks in Gabon in 1996. There was no meaning difference in viral antigen load between survivors and nonsurvivors, only immune responses varied, suggesting that survival is dependent on the initial or innate immune response to infection. Survivors exhibited more pregnant IgM responses, clearance of viral antigen, and sustained T-cell cytokine responses, as indicated past high levels of T-cell-related mRNA in the peripheral blood. In dissimilarity, antibodies specific for the virus were virtually undetectable in fatal cases, and while gamma interferon (IFN-γ) was detected early after infection, T-cell cytokine RNA levels were more indicative of a failure to develop adaptive immunity in the days preceding death.

During infection, at that place is evidence that both host and viral proteins contribute to the pathogenesis of Ebola virus. Increases in the levels of inflammatory cytokines IFN-γ, IFN-α, interleukin-2 (IL-two), IL-10, and tumor necrosis cistron alpha were associated with fatality from Ebola hemorrhagic fever (40). Moreover, in vitro experiments demonstrated that tumor necrosis gene released from filovirus-infected monocytes and macrophages increased the permeability of cultured homo endothelial cell monolayers (12). All the same, other reports take observed an association betwixt elevated levels of IFN-γ mRNA and protection from infection (2), and a protective event of IFN-α and -γ is suggested by the fact that the virus has evolved at least one protein, VP35, that acts as an IFN-α/β antagonist (5). Whether the effects of cytokines are protective or dissentious may depend non merely on the cytokine profile but besides may represent a delicate balance influenced by the road and titer of incoming virus besides as factors specific to the individual host immune response.

VACCINE DEVELOPMENT

Several animal models have been adult to study the pathogenesis of Ebola virus infection and to assess the efficacy of various vaccine approaches. Guinea pigs and nonhuman primates correspond the primary animal models for vaccine evolution because the progression and pathogenesis most closely resemble those of the human illness (x, 46, 47). A murine model was later developed past serial passage of virus in mice (7). Though the model allows the apply of knockout and inbred strains to evaluate genetic determinants of disease, it is considered less predictive of human disease because it relies on a serially passaged, attenuated virus. While symptoms and time course of disease in guinea pigs parallel those in humans, nonhuman primate infection is considered the well-nigh predictive and useful for vaccine development (14).

Live adulterate viruses and recombinant proteins have been used successfully in a variety of vaccines, but the safe and immunogenicity of gene-based vaccines have proven increasingly attractive. Amid the gene-based approaches, naked plasmid Dna has been used successfully in animal models to direct the synthesis of immunogens inside the host cells and has proven helpful in a diversity of infectious diseases (reviewed in references 11 and 38).

Genetic immunization with plasmid Deoxyribonucleic acid was developed in the guinea pig and was the showtime successful vaccine for Ebola virus (47). In this model, NP elicited a primarily humoral response and was less efficacious, while sGP and GP elicited T-cell proliferative and cytotoxic responses every bit well as a humoral response. Protection against lethal challenge was conferred by each of these immunogens when animals were infected within one calendar month of the last immunization, but only GP or sGP provided long-lasting protection. The degree of protection correlated with antibody titer and antigen-specific T-cell responses. Subsequent studies of NP and GP plasmids conferred protective immunity in mice (39), but it is uncertain whether the attenuated murine virus is more sensitive to neutralization than the wild-type virus. Thus, the relative authority of NP, or its requirement as an immunogen for providing long-term protection, remains uncertain.

While DNA vaccines have been highly constructive in rodents, their efficacy in nonhuman primates or humans has been less impressive. Priming-boosting immunization protocols that utilize DNA immunization followed past boosting with poxvirus vectors carrying the genes for pathogen proteins accept yielded dramatically enhanced immune responses in animal studies, with thirty-fold or greater increases in antibody titer from the booster (31). A unlike priming-boosting strategy using replication-defective adenovirus for an Ebola virus vaccine was tested in cynomolgus macaques (36). This report demonstrated the superior immunologic efficacy of this priming-boosting combination for both cellular and humoral responses. These animals displayed consummate immune protection against a lethal challenge of virus, providing the start demonstration of an Ebola virus vaccine arroyo that protects primates confronting infection. Recently, an accelerated vaccination has been developed that confers protection against a lethal virus challenge in nonhuman primates later a single immunization (36a). If this vaccine works similarly in humans, it may be useful in the containment of acute outbreaks by band vaccination.

In summary, an understanding of the mechanisms underlying Ebola virus-induced cytopathic furnishings has facilitated the procedure of vaccine and antiviral therapy development, which has in turn provided new data nearly pathogenesis and the immune response. Ebola virus does non showroom the high degree of variability that other enveloped viruses may use to evade host immunity, but Ebola virus GP alters target-jail cell part and exemplifies a novel strategy for immune evasion that may accept arisen through the evolution of Ebola virus with its natural host. The cytotoxic effects of GP on macrophage and endothelial cell function disrupt inflammatory cell part and the integrity of the vasculature. In addition, by altering the jail cell surface expression of adhesion proteins and immune recognition molecules, Ebola virus may disrupt processes critical to immune activation and cytolytic-T-cell office. These phenomena likely account for the dysregulation of the inflammatory response and the vascular dysfunction characteristic of lethal Ebola virus infection, providing a rationale for focusing on GP equally a target for a preventative vaccine and providing leads for other clinical interventions.

REFERENCES

1. Alvarez, C. P., F. Lasala, J. Carrillo, A. L. Corbi, and R. Delgado. 2002. C-blazon lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J. Virol. 76 :6841-6844. [PMC free article] [PubMed] [Google Scholar]

two. Baize, Southward., E. M. Leroy, 1000.-C. Georges-Courbot, M. Capron, J. Lansoud-Soukate, P. Debre, South. P. Fisher-Hoch, J. B. McCormick, and A. J. Georges. 1999. Lacking humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med. 5 :423-426. [PubMed] [Google Scholar]

3. Baskerville, A., E. T. W. Bowen, Grand. S. Platt, L. B. McArdell, and D. I. H. Simpson. 1978. The pathology of experimental Ebola virus infection in monkeys. J. Pathol. 125 :131-138. [PubMed] [Google Scholar]

4. Baskerville, A., S. P. Fisher-Hoch, Chiliad. H. Neild, and A. B. Dowsett. 1985. Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J. Pathol. 147 :199-209. [PubMed] [Google Scholar]

5. Basler, C. F., X. Wang, East. Muhlberger, 5. Volchkov, J. Paragas, H.-D. Klenk, A. Garcia-Sastre, and P. Palese. 2000. The Ebola virus VP35 protein functions equally a type 1 IFN antagonist. Proc. Natl. Acad. Sci. USA 97 :12289-12294. [PMC gratuitous article] [PubMed] [Google Scholar]

6. Bowen, E. T., One thousand. Lloyd, W. J. Harris, Grand. S. Platt, A. Baskerville, and E. E. Vella. 1977. Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary studies on the aetiological amanuensis. Lancet i :571-573. [PubMed] [Google Scholar]

vii. Bray, M., Thou. Davis, T. Geisbert, C. Schmaljohn, and J. Huggins. 1998. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178 :651-661. [PubMed] [Google Scholar]

8. Chan, S. Y., C. J. Empig, F. J. Welte, R. F. Speck, A. Schmaljohn, J. F. Kreisberg, and M. A. Goldsmith. 2001. Folate receptor-α is a cofactor for cellular entry by Marburg and Ebola viruses. Cell 106 :117-126. [PubMed] [Google Scholar]

9. Colebunders, R., and Thousand. Borchert. 2000. Ebola haemorrhagic fever—a review. J. Infect. forty :xvi-20. [PubMed] [Google Scholar]

10. Connolly, B. 1000., Yard. E. Steele, Grand. J. Davis, T. Due west. Geisbert, Due west. Thousand. Kell, N. Grand. Jaax, and P. B. Jahrling. 1999. Pathogenesis of experimental Ebola virus infection in guinea pigs. J. Infect. Dis. 179 :S203-S217. [PubMed] [Google Scholar]

11. Donnelly, J. J., J. B. Ulmer, J. Westward. Shiver, and One thousand. A. Liu. 1997. DNA vaccines. Annu. Rev. Immunol. 15 :617-648. [PubMed] [Google Scholar]

12. Feldmann, H., H. Bugany, F. Mahner, H. D. Klenk, D. Drenckhahn, and H. J. Schnittler. 1996. Filovirus-induced endothelial leakage triggered past infected monocytes/macrophages. J. Virol. 70 :2208-2214. [PMC complimentary article] [PubMed] [Google Scholar]

13. Feldmann, H., S. T. Nichol, H. D. Klenk, C. J. Peters, and A. Sanchez. 1994. Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology 199 :469-473. [PubMed] [Google Scholar]

14. Geisbert, T. W., P. Pushko, K. Anderson, J. Smith, Thou. J. Davis, and P. B. Jahrling. 2002. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 8 :503-507. [PMC free article] [PubMed] [Google Scholar]

xv. Gupta, M., S. Mahanty, M. Bray, R. Ahmed, and P. E. Rollin. 2001. Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. J. Virol. 75 :4649-4654. [PMC complimentary article] [PubMed] [Google Scholar]

xvi. Ito, H., South. Watanabe, A. Sanchez, M. A. Whitt, and Y. Kawaoka. 1999. Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. J. Virol. 73 :8907-8912. [PMC free article] [PubMed] [Google Scholar]

17. Ito, H., Due south. Watanabe, A. Takada, and Y. Kawaoka. 2001. Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies. J. Virol. 75 :1576-1580. [PMC free commodity] [PubMed] [Google Scholar]

18. Jahrling, P. B., J. Geisbert, J. R. Swearengen, M. P. Jaax, T. Lewis, J. W. Huggins, J. J. Schmidt, J. West. LeDuc, and C. J. Peters. 1996. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch. Virol. 11(Suppl.):135-140. [PubMed] [Google Scholar]

19. Jahrling, P. B., T. W. Geisbert, D. W. Dalgard, E. D. Johnson, T. G. Ksiazek, W. C. Hall, and C. J. Peters. 1990. Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet 335 :502-505. [PubMed] [Google Scholar]

20. Johnson, Thousand. One thousand., J. V. Lange, P. A. Webb, and F. A. Tater. 1977. Isolation and partial characterisation of a new virus causing astute haemorrhagic fever in Zaire. Lancet i :569-571. [PubMed] [Google Scholar]

21. Kilby, J. K., Southward. Hopkins, T. M. Venetta, B. DiMassimo, M. A. Cloud, J. Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, 1000. R. Johnson, One thousand. A. Nowak, G. M. Shaw, and One thousand. Southward. Saag. 1998. Stiff suppression of HIV-1 replication in humans by T-twenty, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4 :1302-1307. [PubMed] [Google Scholar]

22. Kindzelskii, A. L., Z. Yang, G. J. Nabel, R. F. Todd III, and H. R. Petty. 2000. Ebola virus secretory glycoprotein (sGP) diminishes FcγRIIIB-to-CR3 proximity on neutrophils. J. Immunol. 164 :953-958. [PubMed] [Google Scholar]

23. Malashkevich, V. Northward., B. J. Schneider, 1000. L. McNally, M. A. Milhollen, J. X. Pang, and P. S. Kim. 1999. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.nine-Å resolution. Proc. Natl. Acad. Sci. The states 96 :2662-2667. [PMC free article] [PubMed] [Google Scholar]

24. Maruyama, T., 50. L. Rodriguez, P. B. Jahrling, A. Sanchez, A. S. Khan, South. T. Nichol, C. J. Peters, P. W. Parren, and D. R. Burton. 1999. Ebola virus can exist effectively neutralized past antibiotic produced in natural human infection. J. Virol. 73 :6024-6030. [PMC free article] [PubMed] [Google Scholar]

25. Parren, P. West., T. Westward. Geisbert, T. Maruyama, P. B. Jahrling, and D. R. Burton. 2002. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model past passive transfer of a neutralizing human antibiotic. J. Virol. 76 :6408-6412. [PMC free commodity] [PubMed] [Google Scholar]

26. Peters, C. J., and A. Southward. Khan. 1999. Filovirus diseases. Curr. Top. Microbiol. Immunol. 235 :85-95. [PubMed] [Google Scholar]

27. Ploegh, H. Fifty. 1998. Viral strategies of immune evasion. Science 280 :248-253. [PubMed] [Google Scholar]

28. Sanchez, A., A. S. Khan, Southward. R. Zaki, Yard. J. Nabel, T. Thou. Ksiazek, and C. J. Peters. 2001. Filoviridae: Marburg and Ebola viruses, p. 1279-1304. In D. M. Knipe and P. M. Howley (ed.), Fields virology. Lippincott, Williams & Wilkins, Philadelphia, Pa.

29. Sanchez, A., S. G. Trappier, B. Westward. J. Mahy, C. J. Peters, and S. T. Nichol. 1996. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl. Acad. Sci. USA 93 :3602-3607. [PMC free article] [PubMed] [Google Scholar]

30. Sanchez, A., Z. Yang, 50. Xu, 1000. J. Nabel, T. Crews, and C. J. Peters. 1998. Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J. Virol. 72 :6442-6447. [PMC free article] [PubMed] [Google Scholar]

31. Schneider, J., S. C. Gilbert, T. J. Blanchard, T. Hanke, Yard. J. Robson, C. Thou. Hannan, M. Becker, R. Sinden, One thousand. L. Smith, and A. V. Colina. 1998. Enhanced immunogenicity for CD8+ T cell induction and consummate protective efficacy of malaria DNA vaccination past boosting with modified vaccinia virus Ankara. Nat. Med. four :397-402. [PubMed] [Google Scholar]

32. Simmons, G., J. D. Reeves, C. C. Grogan, L. H. Vandenberghe, F. Baribaud, J. C. Whitbeck, East. Shush, Thou. J. Buchmeier, E. J. Soilleux, J. 50. Riley, R. Due west. Doms, P. Bates, and S. Pohlmann. 2003. DC-SIGN and DC-SIGNR demark Ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 305 :115-123. [PubMed] [Google Scholar]

33. Simmons, G., R. J. Wool-Lewis, F. Baribaud, R. C. Netter, and P. Bates. 2002. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J. Virol. 76 :2518-2528. [PMC free article] [PubMed] [Google Scholar]

34. Ströher, U., Eastward. West, H. Bugany, H.-D. Klenk, H.-J. Schnittler, and H. Feldmann. 2001. Infection and activation of monocytes past Marburg and Ebola viruses. J. Virol. 75 :11025-11033. [PMC costless article] [PubMed] [Google Scholar]

35. Sui, J., and Westward. A. Marasco. 2002. Testify against Ebola virus sGP binding to human neutrophils past a specific receptor. Virology 303 :9-14. [PubMed] [Google Scholar]

36. Sullivan, N. J., A. Sanchez, P. E. Rollin, Z.-Y. Yang, and G. J. Nabel. 2000. Evolution of a preventive vaccine for Ebola virus infection in primates. Nature 408 :605-609. [PubMed] [Google Scholar]

36a. Sullivan, N. J., T. W. Geisbert, L. Xu, Z.-Y. Yang, M. Roederer, R. A. Koup, P. B. Jahrling, and G. J. Nabel. 2003. Accelerated vaccination for ebola virus hemorrhagic fever in non-human primates. Nature 424 :681-684. [PMC free article] [PubMed] [Google Scholar]

37. Takada, A., S. Watanabe, H. Ito, K. Okazaki, H. Kida, and Y. Kawaoka. 2000. Downregulation of β1 integrins past Ebola virus glycoprotein: implication for virus entry. Virology 278 :20-26. [PubMed] [Google Scholar]

38. Tighe, H., Grand. Corr, M. Roman, and E. Raz. 1998. Gene vaccination: plasmid DNA is more than just a pattern. Immunol. Today 19 :89-97. [PubMed] [Google Scholar]

39. Vanderzanden, L., 1000. Bray, D. Fuller, T. Roberts, D. Custer, and K. Spik. 1998. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 246 :134-144. [PubMed] [Google Scholar]

40. Villinger, F., P. E. Rollin, Due south. S. Brar, N. F. Chikkala, J. Winter, J. Sundstrom, S. R. Zaki, R. Swanepoel, A. Ansari, and C. J. Peters. 1999. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J. Infect. Dis. 179 :S188-S191. [PubMed] [Google Scholar]

41. Volchkov, V. East., S. Becker, V. A. Volchkova, V. A. Ternovoj, A. Northward. Kotov, S. V. Netesov, and H. D. Klenk. 1995. GP mRNA of Ebola virus is edited past the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 214 :421-430. [PubMed] [Google Scholar]

42. Volchkov, V. East., V. A. Volchkova, E. Muhlberger, L. V. Kolesnikova, K. Weik, O. Dolnik, and H.-D. Klenk. 2001. Recovery of infectious Ebola virus from complementary Deoxyribonucleic acid: RNA editing of the GP gene and viral cytotoxicity. Science 291 :1965-1969. [PubMed] [Google Scholar]

43. Watanabe, S., A. Takada, T. Watanabe, H. Ito, H. Kida, and Y. Kawaoka. 2000. Functional importance of the coiled-coil of the Ebola virus glycoprotein. J. Virol. 74 :10194-10201. [PMC free commodity] [PubMed] [Google Scholar]

44. Weissenhorn, Westward., A. Carfi, K. H. Lee, J. J. Skehel, and D. C. Wiley. 1998. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol. Cell 2 :605-616. [PubMed] [Google Scholar]

45. Wilson, J. A., K. Hevey, R. Bakken, S. Guest, K. Bray, A. L. Schmaljohn, and M. K. Hart. 2000. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287 :1664-1666. [PubMed] [Google Scholar]

46. Wyers, M., P. Formenty, Y. Cherel, L. Guigand, B. Fernandez, C. Boesch, and B. Le Guenno. 1999. Histopathological and immunohistochemical studies of lesions associated with Ebola virus in a naturally infected chimpanzee. J. Infect. Dis. 179 :S54-S59. [PubMed] [Google Scholar]

47. Xu, 50., A. Sanchez, Z. Yang, S. R. Zaki, East. Thousand. Nabel, S. T. Nichol, and G. J. Nabel. 1998. Immunization for Ebola virus infection. Nat. Med. 4 :37-42. [PubMed] [Google Scholar]

48. Yang, Z.-Y., H. J. Duckers, Northward. J. Sullivan, A. Sanchez, E. G. Nabel, and 1000. J. Nabel. 2000. Identification of the Ebola virus glycoprotein every bit the principal viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 6 :886-889. [PubMed] [Google Scholar]

49. Yang, Z.-Y., R. Delgado, L. Xu, R. F. Todd, E. G. Nabel, A. Sanchez, and G. J. Nabel. 1998. Singled-out cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science 279 :1034-1037. [PubMed] [Google Scholar]

fifty. Zaki, S. R., W. Shieh, P. Westward. Greer, C. S. Goldsmith, T. Ferebee, J. Katshitshi, F. Tshioko, Grand. Bwaka, R. Swanepoel, P. Calain, A. S. Khan, Due east. Lloyd, P. Rollin, T. M. Ksiazek, and C. J. Peters. 1999. A novel immunohistochemical assay for the detection of Ebola virus in skin: implications for diagnosis, spread, and surveillance of Ebola hemorrhagic fever. J. Infect. Dis. 179 :S36-S47. [PubMed] [Google Scholar]